Gelonghui reported on November 15 that zhejiang hisun pharmaceutical (600267.SH) stated on the interactive platform that meropenem is currently still in the first round of centralized procurement period, and the sales volume is not large. The company will closely monitor subsequent procurement opportunities; the company has many products and is recovering well through diversified operation. The entire company is striving to reach the performance targets set at the beginning of the year, with the industrial team continuously improving process levels. The cost reduction and efficiency enhancement work has shown initial results this year, and substantial progress in industrial capacity recovery is expected to begin next year.